162 related articles for article (PubMed ID: 8879374)
1. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
[TBL] [Abstract][Full Text] [Related]
2. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte PF
Cancer; 1993 Jul; 72(2):564-8. PubMed ID: 8319188
[TBL] [Abstract][Full Text] [Related]
3. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
4. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
[TBL] [Abstract][Full Text] [Related]
5. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Hrushesky WJ; von Roemeling R; Lanning RM; Rabatin JT
J Clin Oncol; 1990 Sep; 8(9):1504-13. PubMed ID: 2144018
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
7. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Conroy T; Geoffrois L; Guillemin F; Luporsi E; Krakowski I; Spaëth D; Frasie V; Volff D
Cancer; 1993 Oct; 72(7):2190-7. PubMed ID: 8374877
[TBL] [Abstract][Full Text] [Related]
8. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
11. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Vokes EE; O'Brien SM; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 1993; 32(5):347-52. PubMed ID: 8339384
[TBL] [Abstract][Full Text] [Related]
12. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
14. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
16. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Stadler WM; Vogelzang NJ; Vokes EE; Charette J; Whitman G
Cancer Chemother Pharmacol; 1992; 31(3):213-6. PubMed ID: 1464158
[TBL] [Abstract][Full Text] [Related]
17. [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Fujinami K; Ikeda I; Miura T; Kondo I
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1689-91. PubMed ID: 8886046
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
Haarstad H; Jacobsen AB; Schjølseth SA; Risberg T; Fosså SD
Ann Oncol; 1994 Mar; 5(3):245-8. PubMed ID: 8186172
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
[TBL] [Abstract][Full Text] [Related]
20. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
